Krishna Komanduri: Big deal and a win for immunotherapy patients

Krishna Komanduri, Physician in Chief at UCSF Helen Diller Family Comprehensive Cancer Center, made the following post on X:

“This is a big deal and a win for immunotherapy patients.

And consistent with advocacy from the ASTCT 80/20 project which argued the historical role of REMS programs in tcellrx has largely been superseded by cumulative expertise and quality processes.”

Allison Betof Warner, Director of Melanoma Medical Oncology and Solid Tumor Cellular Therapy at Stanford Cancer Institute, retweeted this post on X and added the following:

“Huge win for cell therapy by lowering barriers to care and burden on the healthcare system. Additionally, it reflects growing expertise in our field and shows that requirements can and should change as experience grows. Well done, FDA Oncology
and ASTCT 80/20 project!”

Read further.
Source: Krishna Komanduri/X and Allison Betof Warner/X
.